BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation

NEW HAVEN, Conn., Dec. 27, 2018 — BioXcel Therapeutics, Inc. (“BTI” or “Comp...
read more